AI-Powered Blood Test Revolutionizing Uterine Cancer Screening in NHS Hospitals
Several NHS hospitals are set to implement an innovative AI-powered blood test designed to screen women referred for potential uterine cancer, aiming to reduce the need for invasive diagnostic procedures. This breakthrough could significantly enhance the screening process for postmenopausal women experiencing symptoms such as heavy bleeding.
According to a report by The Guardian, around 90,000 postmenopausal women in England are referred by general practitioners annually for further examination due to symptoms like heavy bleeding. Alarmingly, approximately 10,000 women receive a uterine cancer diagnosis each year, with about 2,700 succumbing to the disease.
This is How the PinPoint Test Works
The PinPoint test, developed by Leeds-based PinPoint Data Science, leverages machine learning technology to evaluate cancer risk using blood markers. It analyzes approximately 30 different markers to categorize patients into low, increased, or high-risk groups. This AI-driven tool is designed to integrate seamlessly into existing cancer referral pathways, providing a cost-effective and efficient screening solution at approximately £30 per test.
The PinPoint test, described as a multi-cancer screening tool, has been applied in diverse cancer areas, including gynecological cancers, lung cancer, and cancers of the gastrointestinal tract, head, and neck. The rollout of this test follows a comprehensive study involving 16,481 patients referred through urgent cancer pathways in Yorkshire, particularly those with symptoms indicative of potential uterine or gynecological cancer.
The study’s findings revealed that one in ten women referred for heavy bleeding were diagnosed with cancer. Notably, the PinPoint test identified 99.1% of cancers as increased or high risk, offering a negative predictive value of 99.8% for women deemed low risk. This high level of accuracy supports its potential to transform current diagnostic practices.
Current Diagnostic Route
Presently, women referred for suspected reproductive system cancers typically undergo a gynecological examination, including a transvaginal ultrasound. This procedure involves the insertion of an ultrasound probe into the vagina, which can cause discomfort for many patients. If cancer remains a concern, patients may require further tests, such as biopsies and hysteroscopies, which examine the uterus’s interior.
The PinPoint test aims to identify women at very low risk, potentially sparing them from unnecessary procedures. It’s estimated that the test could prevent around 18,000 women annually in England from undergoing transvaginal ultrasounds, significantly easing the burden on both patients and healthcare systems.
Professor Sean Duffy, chief medical officer at PinPoint Data Science, emphasized the test’s value in ruling out low-risk cases, streamlining the diagnostic process. Dr. Jacinta Walsh, a GP at King’s Medical Practice in West Yorkshire, noted that the test could reduce the need for multiple GP visits, freeing up resources for other patients.
Tracy Jackson, a consultant gynecologist at Leeds Teaching Hospitals NHS Trust, stated that most women referred under current pathways do not have cancer. She highlighted the PinPoint test’s ability to help triage patients, prioritizing those at higher risk for further investigation.
Other AI Uses in the NHS
The NHS is increasingly incorporating AI technologies to enhance patient care. Recent deployments include MEMORI at Kent and Canterbury Hospital, an AI triage tool within the NHS app, and AI-powered chest X-ray machines for suspected lung cancer pathways. These innovations demonstrate the NHS’s commitment to leveraging AI for improved healthcare outcomes.
NHS England reported that an AI triage tool is anticipated to reach over 200,000 patients within a year and be accessible to all NHS app users by April 2028. Furthermore, the government has pledged £20 million to ensure AI-powered chest X-ray machines are available nationwide by 2029, currently supporting the screening of over four million patients for lung cancer.
While the PinPoint test shows promise, Cancer Research UK emphasized the need for further research to fully understand its impact on patient outcomes, referral decisions, and the NHS’s diagnostic capacity. Early detection remains crucial in cancer treatment, and tools like the PinPoint test could play a pivotal role in identifying cases at an early stage.
For more information on this topic, visit Here.
Want to learn more about AI and big data from industry leaders? Check out the AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and occurs alongside other leading technology events. Click here for more information.
AI News is operated by TechForge Media. Discover more upcoming enterprise technology events and webinars here.
“`
